GlobeNewswire Inc | Nov 11, 2021 07:30AM EST

November 11, 2021

BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the companys co-founder, president, and chief executive officer, will participate in the following virtual investor conferences:

-- The 2021 Jefferies London Virtual Healthcare Conference. The presentation will be available on-demand beginning at 3:00 a.m. ET/8:00 a.m. GMT on Thursday, November 18, 2021. -- The Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will be available on-demand beginning at 10:00 a.m. ET on Monday, November 22, 2021.

A replay of the pre-recorded presentations can be accessed from theInvestor & Newssection of Inozymes website underevents and will be available for up to 60 days following the events.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

Inozyme Pharmawas founded in 2017 byJoseph Schlessinger, Ph.D.,Demetrios Braddock, M.D., Ph.D., andAxel Bolte, MSc, MBA, with technology developed byDr. Braddockand licensed fromYale University. For more information, please visitwww.inozyme.com.

ContactsInvestors:Inozyme PharmaStefan Riley, Director of Investor Relationsstefan.riley@inozyme.com

Media: SmithSolve Matt Pera973-886-9150matt.pera@smithsolve.com